Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Friday, February 13, 2015

PCORI Announces $50 million in Hepatitis C Research Funding

Hepatitis C virus (HCV) research recently received a significant boost with a commitment of up to $50 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for comparative clinical effectiveness research (CER) studies on the best ways to diagnose and treat HCV infection.  PCORI posted application materials earlier this month and announced a May 5, 2015 application deadline.

“HCV is a major health threat that can have devastating consequences for infected people and their families,” said PCORI Executive Director Joe Selby, MD, MPH, in a press release announcing the funding commitment. “Recently approved medications are immensely promising and offer vast improvements over previous therapies, but as yet there’s no ‘real-world’ evidence of their long-term effectiveness nor comparative evidence to help inform decisions about screening, diagnosis, and treatment of HCV.”

Read more...

No comments:

Post a Comment